Akebia Therapeutics (AKBA) Misses Q4 EPS by 5c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.05), $0.05 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $57.62 million versus the consensus estimate of $56.18 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Pentagon-Backed Oil Company Is Set to Vie for Chevron's Crown in Venezuela - WSJ
• MARA amends Texas power site purchase agreement, posts $100M deposit